Ledipasvir

CAT#: H314253

CAS#: 1256388-51-8

Description: Ledipasvir, also known as GS-5885; is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni). The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin. (http://en.wikipedia.org/wiki/Ledipasvir)

img

Synthetic Routes

Ledipasvir - Synthetic Route 1

Ledipasvir route01

Synthetic reference

Link, John O.; Taylor, James G.; Xu, Lianhong; Mitchell, Michael; Guo, Hongyan; Liu, Hongtao; Kato, Darryl; Kirschberg, Thorsten; Sun, Jianyu; Squires, Neil; Parrish, Jay; Kellar, Terry; Yang, Zheng-Yu; Yang, Chris; Matles, Mike; Wang, Yujin; Wang, Kelly; Cheng, Guofeng; Tian, Yang; Mogalian, Erik; Mondou, Elsa; Cornpropst, Melanie; Perry, Jason; Desai, Manoj C. Discovery of Ledipasvir (GS-​5885)​: A Potent, Once-​Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry. Volume 57. Issue 5. Pages 2033-2046. Journal; Online Computer File. (2014).

Ledipasvir - Synthetic Route 2

Ledipasvir route02

Synthetic reference

Ye, Fangguo. Process for preparation of ledipasvir and intermediates thereof. Assignee Shanghai Twisun Bio-Pharm Co., Ltd., Peop. Rep. China. WO 2018113277. (2018).

Ledipasvir - Synthetic Route 3

Ledipasvir route03

Synthetic reference

Vetukuri, Prasada Raju V. N. K. V.; Gilla, Goverdhan; Rapolu, Rajesh Kumar; Chigurupati, Krishna Prasad. An improved process for the preparation of HCV inhibitor. Assignee Granules India Limited, India. IN 2014CH06558. (2016).